Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
In vitro effects of vandetanib...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival
Bibliographic Details
Main Authors:
Brave, SR
,
Marshall, G
,
Wainwright, A
,
James, N
,
Acheson, N
,
Howard, Z
,
Ratcliffe, K
,
Speake, G
,
Barry, S
,
Hickinson, D
,
Ryan, A
Format:
Journal article
Published:
2007
Holdings
Description
Similar Items
Staff View
Similar Items
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
by: Brave, SR, et al.
Published: (2011)
A secondary RET mutation in the activation loop conferring resistance to vandetanib
by: Takashi Nakaoku, et al.
Published: (2018-02-01)
A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
by: Pacey, S, et al.
Published: (2016)
Deciphering the resistance mechanism of RET kinase mutant against vandetanib and nintedanib using molecular dynamics simulations
by: Guodong Zheng, et al.
Published: (2021-12-01)
Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
by: Sami Znati, et al.
Published: (2020-07-01)